Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.17199 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Nucleophosmin 1 (NPM1) mutations represent one of the most frequent genetic alterations in acute myeloid leukemia (AML). However, the prognostic significance of concurrent molecular abnormalities and clinical features in NPM1-mutated AML remains to be fully elucidated.
Methods: We retrospectively analyzed 73 adult AML patients with NPM1 mutations.
Novel small-molecule therapies for myelodysplastic syndromes with IPSS-R ⩾3.5 in patients aged 60 or older: current landscape and challenges.
Ther Adv Hematol
September 2025
Department of Hematology, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, Shandong 266000, China.
Myelodysplastic syndromes (MDS), particularly in older adults aged 60 years and above, present significant therapeutic challenges due to poor prognosis and limited treatment options. Higher-risk MDS (HR-MDS), defined by the Revised International Prognostic Scoring System score of ⩾3.5, is characterized by increased myeloblasts, severe cytopenia, and a median survival of <2 years.
View Article and Find Full Text PDFFDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgery.
Clin Cancer Res
September 2025
United States Food and Drug Administration, Silver Spring, Maryland, United States.
On August 6, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to vorasidenib (VORANIGO, Servier Pharmaceuticals, LLC) for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 or 2 (IDH1 or IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection.
View Article and Find Full Text PDFMonitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia.
Br J Haematol
September 2025
Laboratory of Hematology, Biology and Pathology Center, CHU Lille, Lille, France.
Measurable residual disease (MRD) is a strong prognostic factor in acute myeloid leukaemia (AML). Next-generation sequencing (NGS) offers promise but must distinguish true signal from background. We assessed MRD in 98 adult AML patients in first complete remission after intensive chemotherapy using a duplex unique molecular identifier (UMI)-based NGS capture panel.
View Article and Find Full Text PDFIDH1-dependent m6A methylation defines transcriptomic heterogeneity in glioma.
medRxiv
August 2025
Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Gliomas are biologically heterogeneous brain tumors with marked differences in clinical behavior based on the IDH1 mutation status. While epigenetic dysregulation is well characterized, the contribution of RNA modifications, particularly N6-methyladenosine (m6A), remains underexplored. Using direct RNA nanopore sequencing of patient-derived gliomas, we generated the first isoform-resolved m6A maps across IDH1-mutant and wild-type tumors.
View Article and Find Full Text PDF